Want to see CVSI full AI Analyst Report?
CVSI Stock Chart & Stats
$0.02
>-$0.01(-5.72%)
At close: 4:00 PM EDT
$0.02
>-$0.01(-5.72%)
Day’s Range― - ―
52-Week Range$0.01 - $0.10
Previous CloseN/A
Volume53.78K
Average Volume (3M)470.92K
Market Cap
$2.94M
Enterprise Value$5.97
Total Cash (Recent Filing)$266.00K
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta0.52
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding225,829,130
10 Day Avg. Volume394,003
30 Day Avg. Volume470,923
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.71
Price to Sales (P/S)0.82
P/FCF Ratio-21.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stable Gross MarginA gross margin near 49% indicates the product portfolio retains meaningful economic value despite weaker demand. Maintaining this level can support future operating leverage if revenue stabilizes, although profitability still depends on restoring sufficient sales scale and controlling expenses.
New Product InnovationNew products already contribute a substantial share of revenue, showing that innovation is influencing the commercial mix rather than remaining only a development effort. Continued launches, including personalized healthy-aging products, could broaden demand and reduce reliance on older offerings.
Expense DisciplineReducing operating expenses while preserving a gross margin near 49% demonstrates management is taking concrete steps to align the cost base with lower sales. Sustained discipline could narrow operating losses and improve the company’s ability to benefit when product demand recovers.
Bears Say
Declining RevenueThe decline in both revenue and units sold points to weakening underlying demand or distribution productivity, not merely a pricing effect. Persistent volume contraction would limit operating leverage, reduce reinvestment capacity, and make recovery dependent on successful new-product adoption.
Recurring LossesOngoing operating and net losses show that the company’s roughly 49% gross margin is not currently sufficient to cover its operating structure. Continued losses can erode equity and constrain investment in marketing, innovation, and channel expansion over the coming quarters.
Negative Cash GenerationNegative operating and free cash flow means the business is not yet self-funding, even though the burn rate has improved versus prior years. If profitability does not recover, continued cash use could increase reliance on external capital and reduce strategic flexibility.
CV Sciences News
CVSI FAQ
What was CV Sciences Inc’s price range in the past 12 months?
CV Sciences Inc lowest stock price was $0.01 and its highest was $0.10 in the past 12 months.
What is CV Sciences Inc’s market cap?
CV Sciences Inc’s market cap is $2.94M.
When is CV Sciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CV Sciences Inc’s earnings last quarter?
Currently, no data Available
Is CV Sciences Inc overvalued?
According to Wall Street analysts CV Sciences Inc’s price is currently Overvalued.
Does CV Sciences Inc pay dividends?
CV Sciences Inc does not currently pay dividends.
What is CV Sciences Inc’s EPS estimate?
CV Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CV Sciences Inc have?
CV Sciences Inc has 225,829,130 shares outstanding.
What happened to CV Sciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CV Sciences Inc?
Currently, no hedge funds are holding shares in CVSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CV Sciences Inc
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.
CVSI Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
cbdMD
―
Cosmos Holdings
―
IM Cannabis Corp
―
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
11.80% Insiders
<0.01% Other Institutional Investors
88.20% Public Companies and
Individual Investors










